Compare AstraZeneca plc (AZN) vs Lemonade Inc (LMND) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Lemonade (LMND) trades at $70.62, up 0.16% on the day, with a bullish technical signal from moving averages and ADX indicators. Revenue growth is robust, increasing from $257M in 2022 to $738M in 2025, while net losses are narrowing, with the net margin improving from -116.02% to -22.43% over the same period. Recent news highlights expansion into new states and a renegotiated reinsurance program, improving cost structure and capital efficiency.

The outlook is mixed; strong revenue growth and narrowing losses present a long-term opportunity, but the stock trades above the consensus price target of $67.00, with 40% of analysts rating it a sell. Key risks include persistent unprofitability, high valuation multiples, and execution challenges in scaling the AI-driven insurance model. Positive cash flow from operations is projected for 2026, a potential inflection point.